Xilio Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $161.64M
- P/E (TTM)
- –
- Dividend yield
- –
About Xilio Therapeutics
Pharmaceutical Preparations, SIC 2834
Xilio Therapeutics is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for cancer treatment. Using proprietary protein engineering and masking technology, the company designs biologic therapies, including masked multi-specific molecules, engineered to activate selectively within the tumor microenvironment through tumor-specific proteases. These therapies aim to deliver localized therapeutic activity while minimizing the toxicities commonly caused by systemic exposure. The company develops programs for individuals living with cancer and engages in strategic collaboration and licensing agreements with biopharmaceutical partners, including Gilead Sciences and AbbVie.
The company operates its principal executive offices in Waltham, Massachusetts. Its activities also involve research, development, and manufacturing collaborations with global partners, including manufacturing and research operations conducted through WuXi Biologics in China. Corporate governance and business operations are conducted under Delaware jurisdiction.
Summary of the business section of Xilio Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Xilio Therapeutics, Inc.
- Headquarters
- Waltham, MA
- Address
- 828 Winter Street 02451
- Phone
- (617) 833-1027
- Website
- xiliotx.com
- Employees
- 76, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- XLO
- Exchange
- Nasdaq
- IPO date
- Oct 22, 2021
- Shares outstanding
- 6M, Mar 18, 2026
- Public float
- $34.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-14 reverse, Mar 23, 2026; 1-for-14 reverse, Mar 16, 2026
- SEC CIK
- 1840233
- CUSIP
- 98422T209
- ISIN
- US98422T2096
- EIN
- 85-1623397
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Rene Russo | PRESIDENT AND CEO, Director | 325,422 |
| Christopher James Frankenfield | Chief Financial Officer | 24,766 |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | 6,371 |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | 33,250 |
| Yuan Xu | Director | – |
| Sara Bonstein | Director | – |
| Robert W. Ross | Director | – |
| James Samuel Shannon | Director | 10,000 |
| Aoife Brennan | Director | – |
| Daniel J. Curran | Director | – |
| Akintunde Olatokumbo Bello | Director | – |
| Cheryl R. Blanchard | Director | – |
| Christina Rossi | Director | – |
| Paul J. Clancy | Director | – |
Employees
Headcount reported in annual reports
“As of February 28, 2026, we had 76 full-time employees, including 30 employees with M.D., Pharm.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 3, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 28, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 8, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 13, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 19, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 22, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 18, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |